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T cellsMultiple sclerosis (MS) is themost common chronic inﬂammatory demyelinating disease of the central nervous
system (CNS) in young adults. Chronic treatments with histone deacetylase inhibitors (HDACis) have been re-
ported to ameliorate experimental autoimmune encephalomyelitis (EAE), a rodentmodel ofMS, by targeting im-
mune responses. We have recently shown that the HDAC inhibition/knockdown in the presence of thyroid
hormone (T3) can also promote oligodendrocyte (OL) differentiation and expression of myelin genes in neural
stem cells (NSCs) and oligodendrocyte precursors (OPCs). In this study, we found that treatment with an
HDACi, valproic acid (VPA), and T3, alone or in combination, directly affects encephalitogenic CD4+ T cells.
VPA, but not T3, compromised their proliferation, while both molecules reduced the frequency of IL-17-
producing cells. Transfer of T3, VPA and VPA/T3 treated encephalitogenic CD4+ T cells into naïve rats induced
less severe EAE, indicating that the effects of thesemolecules are persistent and do not require theirmaintenance
after the initial stimuli. Thus, we investigated the effect of acute treatment with VPA and L-thyroxine (T4), a pre-
cursor of T3, on myelin oligodendrocyte glycoprotein-induced EAE in Dark Agouti rats, a close mimic of MS. We
found that a brief treatment after disease onset led to sustained amelioration of EAE and prevention of inﬂamma-
tory demyelination in the CNS accompanied with a higher expression of myelin-related genes in the brain.
Furthermore, the treatment modulated immune responses, reduced the number of CD4+ T cells and affected
the Th1 differentiation program in the brain. Our data indicate that an acute treatment with VPA and T4 after
the onset of EAE can produce persistent clinically relevant therapeutic effects by limiting the pathogenic immune
reactions while promoting myelin gene expression.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).tal autoimmune encephalomy-
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Multiple sclerosis (MS) is the most common chronic inﬂammatory
demyelinating neurodegenerative disease of the central nervous system
(CNS) and the leading cause of non-traumatic neurological disability in
young adults. The etiology of MS involves interplay between environ-
mental factors and multiple susceptibility genes (IMSGC, 2011).
Myelin-speciﬁc T cells are found with an increased frequency and activ-
ity inMS patients (Olsson et al., 1990). Moreover, anMS-like disease can
be induced in rodents with the transfer of CD4+ T cells reactive against
myelin antigens (Goverman, 2009). Inﬁltration of autoreactive cells trig-
gers a cascade of immunological reactions that targetmyelin sheaths and
myelin-producing oligodendrocytes, and eventually cause permanentthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ing–remitting disease course characterized by recurrent episodes of neu-
rological deﬁcits, considered to be clinical manifestations of acute
inﬂammatory demyelination, followed by periods of remission. MS ther-
apies act via immunosuppressive or immunomodulatory mechanisms
and are effective only in the relapsing–remitting stage. The permanent
neuronal loss that starts early and characterizes the progressive stage
of MS remains untreatable. Besides the need for more speciﬁc effects
on the immune system, future therapeutic strategiesmust also target re-
generation of oligodendrocytes and neurons (Deshmukh et al., 2013;
Fancy et al., 2011).
To this aim, histone deacetylase inhibitors (HDACis) are a possible
treatment for MS. Inhibition of histone deacetylases has the ability to
prevent or treat many inﬂammatory disease models in rodents (de
Zoeten et al., 2010; Glauben et al., 2006; Leoni et al., 2005; Lin et al.,
2007; Mishra et al., 2003; Nishida et al., 2004; Saouaf et al., 2009;
Zhang et al., 2010). Several HDACis are already in clinical use: valproic
acid (VPA) for CNS disorders like epilepsy, migraine and psychosis
(Chiu et al., 2013; Gerstner et al., 2008), and vorinostat and romidepsin
for cutaneous T cell lymphoma (Campas-Moya, 2009; Mann et al.,
2007). These HDACis act on epigenetic mechanisms by interfering with
the function of histone deacetylases, which remove the acetyl groups
from lysine residues in histones leading to the formation of a transcrip-
tionally inactive chromatin at a majority of regulatory promoters. In
the immune system, HDAC inhibition affects antigen presentation, sig-
naling, proinﬂammatory mediator production, and expression of MHC
II and co-stimulatory molecules on APCs (Kramer et al., 2009;
Sebastian et al., 2008; Song et al., 2011). Reduction of IL-2 production, an-
ergy and apoptosis of T cells are induced by HDACis, which also affect
proliferation and cytokine production in Th1 cells in vitro (Brogdon
et al., 2007; Dagtas et al., 2009; Edens et al., 2006; Moreira et al., 2003).
In addition, HDACis can promote the frequency and activity of regulatory
cells such as Foxp3+ Tregs (de Zoeten et al., 2010; Lucas et al., 2009;
Saouaf et al., 2009; Tao et al., 2007) and IL-10-producing suppressivemy-
eloid (Villagra et al., 2009) and Tr1 cells (Lee et al., 2012).
Experimental autoimmune encephalomyelitis (EAE) has beenwidely
used to study pathogenic mechanisms shared with MS and to develop
therapies and biomarkers (Steinman and Zamvil, 2006). Chronic HDACi
treatment has been reported to prevent clinical signs of EAE in rats
(Zhang et al., 2012) and mice (Camelo et al., 2005; Ge et al., 2013; Lv
et al., 2012). HDAC inhibition targets the immune system resulting in
the reduction of IFN-γ-producing Th1 and IL-17-producing Th17
CD4+ T helper lymphocytes in the periphery (Ge et al., 2013; Lv et al.,
2012) and CNS (Lv et al., 2012) in murine EAE. HDACis also induce
changes in T helper cytokine expression in rat EAE (Zhang et al., 2012).
While HDACi effects are signiﬁcant when aggressive daily preventive
treatments are given (Ge et al., 2013; Lv et al., 2012; Zhang et al.,
2012), treatments after the onset of disease, as would occur in MS, dem-
onstrate onlymild amelioration in Lewis rats (Zhang et al., 2012) and still
require continuous daily HDACi use for efﬁcacy in mice (Lv et al., 2012).
HDACs can be evicted from speciﬁc loci at the chromatin by thyroid
hormone (T3) treatment. T3 can bind to speciﬁc HDAC-bound nuclear re-
ceptors, inducing allosteric modiﬁcations and HDAC release (Perissi et al.,
2010). Interestingly, an acute therapeutic treatment with L-thyroxine
(T4), which is converted in target tissues to the active compound T3,
leads to mild EAE amelioration in Lewis rats, but not in Dark Agouti
(DA) rats (Fernandez et al., 2004). T3 appears to target directly the CNS
instead of the immune system, with increased expression of markers for
oligodendrocyte precursor cells (OPCs) and accelerated remyelination
(Fernandez et al., 2004). Remyelination can be induced in demyelination
models in rodents (including EAE) and in MS by recruitment of adult
OPCs of the CNS and/or neural stem cells (NSCs) from the subventricular
zone (SVZ) of the brain, followed by differentiation into OLs and
myelination (Fancy et al., 2011; Nait-Oumesmar et al., 2007; Tepavcevic
et al., 2011; Zawadzka et al., 2010). SVZ NSCs and OPCs are recruited to
the sites of lesions in MS, where they differentiate and promoteremyelination in early stages of disease. However, OPCs eventually fail
to remyelinate leading to disability progression. Interestingly,we have re-
cently shown that exposure of embryonic NSCs to HDAC inhibitors in the
absence of T3 leads to neuronal differentiation, while they promote in-
creased OL differentiation and expression ofmyelin genes in the presence
of T3 (Castelo-Branco et al., 2014). In addition, knockdown of HDAC2 in
the presence of T3 in NSCs and OPCs also leads to spontaneous OL differ-
entiation (Castelo-Branco et al., 2014). Thus, HDAC inhibition and T3 can
synergize for terminal oligodendrocyte differentiation in the CNS.
In this study, we investigated the effects of combinatorial HDAC in-
hibition and thyroid hormone treatment on the immune system and
CNS in the context of EAE. We observed that treatment with VPA, T3
and VPA/T3 directly affects encephalitogenic CD4+ T cells, which,
upon transfer, induced less severe EAE compared to untreated T cells.
Our results indicate that the mechanisms by which T3 and VPA affect
encephalitogenic CD4+ T cells and the immune system in EAE are dis-
tinct and subsist even in the absence of the original stimuli. These ﬁnd-
ings, together with our previous results showing synergy between VPA
and T3 on oligodendrocyte differentiation (Castelo-Branco et al., 2014),
prompted us to investigate whether acute co-treatment with VPA and
T4 at a critical windowwhen T cells andOPC/NSCs are present/recruited
to lesions sites attenuated disease progression. Strikingly, an acute three
alternate day treatmentwith VPA in combinationwith T4 initiated after
the clinical onset of EAE in DA rats signiﬁcantly ameliorates clinical
signs, with persistent and sustained effects. Acute treatment with VPA
and T4 at the onset of EAE: 1) induced higher expression of myelin
genes; 2) modulated the CD4+ T cell response at the periphery and in
the CNS; and 3) prevented spread of inﬂammatory demyelination to
the brain. Taken together, these results suggest that combined acute
treatment with HDACis and T3 (or its precursor T4) can be an alterna-
tive therapeutic approach for MS to chronic HDACi treatment, targeting
both inﬂammation and remyelination and thereby ameliorating clinical
symptoms.
Materials and methods
Experimental animals
Inbred DA/Kini rats are from the local colony at the animal facility at
Karolinska Hospital (Stockholm, Sweden), originally obtained from the
Zentralinstitut für Versuchstierzucht (Hanover, Germany), or from
Harlan Laboratories (Blackthorn, UK). Animals were kept in a
pathogen-free and climate-controlled environment in polystyrene
cages containing aspen wood shavings with free access to standard ro-
dent chow and water with regulated 12-hour light/dark cycles. All ex-
periments were performed in accordance with the ethical permit
approved by Stockholms norra djurförsöksetiska nämnd (North
Stockholm animal ethics committee).
Induction of passive and active EAE
Passive EAE was induced by transfer of myelin basic protein (MBP)-
speciﬁc T cell lines. For generation of T cell lines animals were injected
s.c. in the tail base with a 200 μl inoculum containing 100 μg
gpMBP63–88 peptide (EZBiolab, IN, USA) emulsiﬁed 1:1 with Freund's
adjuvant containing 200 μg Mycobacterium tuberculosis (strain H37
RA; Difco Laboratories, Detroit, MI). Single-cell suspension was pre-
pared from inguinal lymph nodes 10 days post immunization (p.i.)
and cellswere cultured three days inDMEM(Sigma-Aldrich) containing
1% normal rat serum and 20 μg/ml gpMBP63–88 peptide and irradiated
thymocytes, followed by expansion with IL-2 containing supernatant
from MLA cell cultures for ﬁve days after which T cells were separated
using Ficoll (GE Healthcare Sciences) density gradient. The IL-2 expan-
sion and gpMBP63–88 restimulation were repeated one more cycle be-
fore transfer. After separation on the Ficoll density gradient, cells were
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i.v. into 8–10 week old age-matched naïve rats.
Active EAE was induced with recombinant myelin oligodendrocyte
glycoprotein (MOG), amino acids 1–125 from the N terminus, which
was expressed in Escherichia coli andpuriﬁed to homogeneity by chelate
chromatography. Active EAE induced by MOG closely resembles MS,
while MBP-induced EAE is a monophasic inﬂammatory disease, thus
the choice of MOG for our experiments. The puriﬁed protein, dissolved
in 6M urea, was dialyzed against PBS to obtain a physiological prepara-
tion. Age-matched rats were anesthetized with isoﬂurane (Forane,
Abbott Laboratories, Chicago, IL, USA) and injected s.c. in the tail base
with a 200 μl inoculum containing rMOG in PBS, emulsiﬁed 1:1 with in-
complete Freund's adjuvant (Sigma-Aldrich, St. Louis, MO, US).
Rats were monitored daily for weight loss and clinical signs of EAE as
follows: 0= no detectable clinical signs, 1 = tail weakness- or paralysis,
2 = hind limb hemi- or paraparesis, 3 = hind limb paralysis and 4 =
tetraplegy ormoribund. The following disease parameters were assessed
for each animal: onset of EAE (the ﬁrst day with clinical disease manifes-
tation), maximum EAE score (the highest clinical score observed during
EAE), cumulative EAE score (the sumof daily clinical scores) and duration
of EAE (the number of days with manifested disease).
Acute VPA/T4 treatment of active EAE
Acute treatment of active EAEwas initiated after the onset of disease
i.e. when the majority of animals displayed clinical signs of EAE or
weight loss. Animals were randomized into the treatment group that
received 200 mg/kg VPA (Sigma, P4543) i.p. three times daily and
0.2 mg/animal L-thyroxin (Sigma, 89430) s.c. once daily (Fig. 3E).
These treatments were given 2 additional times, every second day (in
a total of three alternate treatment days, spread over a period of ﬁve
days, Fig. 3E). The doses of VPA and T4 are in the range, or even cumu-
latively lower, than the doses reported in other similar studies where
the effects of these compounds were studied in rodent EAE models
(Fernandez et al., 2004; Lv et al., 2012; Zhang et al., 2012). The vehicle
treated group received injectionswith the carrier (saline/PBS). Four dif-
ferent experiments were performed with either only male rats (Fig. 3A,
treated with VPA/T4 (n = 8) and vehicle (n = 6)) or female rats (Figs.
3B, C and D, treated with VPA/T4 (n= 11, 15 and 15, respectively) and
vehicle (n = 10, 15 and 15, respectively)). The treatment with VPA/T4
was initiated at the onset (Figs. 3A and C) or three–four days after the
onset of EAE (Figs. 3B and D).
VPA/T3 treatment of MBP-speciﬁc T cell lines
In the last restimulation/expansion cycle with gpMBP63–88/IL-2, T
cell lines were divided into the VPA/T3 treatment and control groups.
The treatment group received 1 mM VPA and/or 340 ng/ml T3 for ﬁve
days prior to injection into naïve rats, with VPA/T3 replacement after
48 h and addition of VPA only 24 h prior to the injection. The control
group was kept in the corresponding medium. The doses of VPA, T3
and VPA/T3 in vitro used are well established in the literature and can
lead to chromatin and phenotypical changes in T cells (Fig. 1C), neural
stem cells and OPCs (Castelo-Branco et al., 2014). For qRT-PCR analysis
(Supplementary Fig. 2, n = 2 per group), treatments were done at time
0 for all three collection time points (6 h, 48 h and 96 h), and addition-
ally added at 48 h for the 96 h collection time point.
Isolation of splenocytes and cells from the CNS
Animals were perfused with PBS containing Heparin (2500 IU/l)
under isoﬂurane anesthesia. The spleens and lymph nodes were extract-
ed and placed in DMEM (Gibco-BRL, Grand Island, NY, USA) enriched
with 5% FCS, 1% L-glutamine, 1% penicillin–streptomycin, 1% pyruvic
acid (all from Life Technologies, Paisley, Scotland) and 50 μM 2-
Mercaptoethanol (Gibco-BRL). Spleens and lymph nodes weremechanically separated. Splenocytes were subjected to erythrocyte
lysis using 0.84% NH4Cl pH 7.2–7.4 (Sigma-Aldrich). For cytokine mea-
surements, 0.5 × 106 cells from lymph nodes were plated per well in
96-well U-bottom plates and stimulated 48 h with Concanavalin A
(2.5 μg/ml).
Brains and spinal cords were extracted and placed separately in
20 ml of a 50% Percoll solution containing 50 U/ml DNAse I (Roche Ap-
plied Science). The tissues were dissociated using glass homogenizers,
underlaid with 63% Percoll solution, and ﬁnally overlaid with a 30%
Percoll solution. Samples were spun at 1000 g for 30min at 8 °C, myelin
was discarded and the whole intermediate layer containing glial cells
and leukocytes (approximately 30 ml) was collected, further diluted
in HBSS and spun at 600 g for 15 min. The cell pellet was resuspended
in PBS and divided into 3 even fractions, two used for ﬂow cytometry
and one for qPCR. The Percoll gradient was generated by dissolving
Percoll to 90% in 10 × HBSS (both from Sigma-Aldrich, Schnelldorf,
Germany), and further diluting it to 30%, 50% or 63% in 1 × HBSS.
Flow cytometry analysis
For the assessment of major cell populations, splenocytes were
stained for surface CD161, γδ TCR, CD4, CD3, CD8a and CD45RA (all
from BD Biosciences), while cells of the oligodendrocyte lineage were
stained for O4 (Miltenyi Biotec), followed by ﬁxation/permeabilization
with the transcription factor staining buffer set from eBioscience and in-
tracellular staining for the proliferation marker Ki67 (BD Biosciences)
and Foxp3 (eBioscience). Gene expression analysis on O4 enriched
cells (by magnetic sorting, using the same antibody used by FACS)
from the brain and spinal cord of healthy rats indicates that these cells
are highly enriched in oligodendrocyte genes such as Plp, Mbp and
CNPase, compared to the negative fraction (data not shown). For the as-
sessment of cytokine production, lymph node cells, CNS-derived cells
and MBP-speciﬁc in vitro expanded T cells were stimulated with PMA
(50 ng/ml), ionomycin (1 μg/ml) and Golgi Plug (1 μl/ml) in complete
medium for 4 h at 37 °C followed by surface staining with CD3 and
CD4 for lymph nodes and CD11b and CD4 for CNS cells. After ﬁxation/
permeabilization as described above, cells were stained with antibodies
to IFN-γ and Ki67 (both from BD Biosciences) as well as IL-17A and
Foxp3 (both from eBioscience). All surface stainings were done in PBS
containing LIVE/DEAD® ﬁxable far-red dead cell exclusion dye (Life
Technologies). Cells were acquired in a Gallios ﬂow cytometer and ana-
lyzed with the Kaluza software (both from Beckman Coulter). For the
spleens and lymph nodes, a minimum of 105 events per organ were
acquired, while 5 × 104 cells were acquired forMBP-speciﬁc in vitro ex-
panded T cells. Brain and spinal cord samples were carefully handled
throughout the experiment and resuspended in equal volumes, follow-
ed by acquisition by ﬁxed time in the ﬂow cytometer, allowing for an
approximate quantiﬁcation of cell numbers inﬁltrating the given
organ and allowing for comparison betweendifferent treatment groups.
Western blot
For immunoblot analysis, cell pellets were resuspended in 2×
Laemmli buffer, boiled for 5 min at 95 °C and sonicated for 5 min at
high power 30 sec on/30 sec off cycles to shear genomic DNA. Proteins
were separated by SDS-PAGE, transferred to PVDF membranes pre-wet
in methanol (GE Healthcare) using wet transfer and incubated in
blocking solution (5% milk in TBS containing 0.1% Tween) for 1 h at
room temperature. Membranes were incubated with primary antibody
at 4 °C overnight and appropriate HRP-conjugated secondary antibody
for 2 h at room temperature. Membranes were then incubated for
enhanced chemiluminescence (GE Healthcare) and proteins were visu-
alized on a ChemiDoc™ XRS imaging system (Bio-Rad). Primary anti-
bodies, diluted in blocking solution were used against acetyl-histone
H3 (Lys9) (α-H3K9ac, Cell Signaling, #9671 at 1:1000 dilution) and
GAPDH (α-GAPDH, Cell Signaling, #5174 at 1:1000 dilution).
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Fig. 1. Treatment ofMBP-speciﬁc T cell lines with VPA and VPA/T3 increases histone acetylation and reduces T cell proliferation and frequency of IL-17-producing cells. (A, B) Flow cytom-
etry analysis of proliferationmarker Ki67 and Th1/Th17 cytokines, IL-17 and IFN-γ in T3, VPA, VPA/T3 and vehicle treated T cells (n= 3 per group) prior to injection to naïve DA recipients
(Fig. 2). (C) Western blot analysis of lysine acetylation on histone H3 in untreated cells and T3, VPA, VPA/T3 and vehicle treated T cells 3 h after the second treatment. Representative ex-
periments are shown. Error bars represent SEM on technical replicates with 5 × 104 cells acquired per sample. Differences in cell frequencies were calculated with 1-way ANOVA with
Kruskal–Wallis test for multiple comparisons (p b 0.05 = *, p b 0.01 = **, p b 0.001 = ***).
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RNAwas puriﬁed using anRNeasyMini kit ormiRNeasyMicro kit for
CNS samples (Qiagen, Hilden, Germany), according to themanufacturer
protocols, including DNase I treatment. cDNA was subsequently pre-
pared with the iScript kit (Bio-Rad, Hercules, USA) or High Capacity
cDNA Reverse Transcription Kit (Life Technologies) for CNS samples.
Quantitative real-time PCR was performed using a BioRad CFX384
Touch real-time PCR system with a three-step PCR protocol (95 °C for
3 min followed by 40 cycles of 95 °C for 10 s, 60 °C for 30 s and 72 °C
for 30 s followed by melt curve analysis), using SYBR Green as the
ﬂuorophore (Bio-Rad). Cycle of threshold (Ct), efﬁciencies and melt
curves were analyzed in CFX Manager software (Bio-Rad) and relative
expression was calculated in relation to the mean of housekeeping
genes, hypoxanthine phosphoribosyltransferase (Hprt) and ubiquitin
C, using 2−ΔΔCt. For Fig. 4 and Supplementary Fig. 2, qPCR was per-
formed in 7900HT Fast Real-Time PCR System (Applied Biosystems),
with a 2 step qPCR protocol (95 °C for 20 s followed by 40 cycles of
95 °C for 1 s, 60 °C for 20 s and 95 °C for 15 s followed by melt curve
analysis) and the FAST SYBR GreenMaster mix. Standard curve method
was used for analysis. Samples were normalized by the geometrical
mean of the housekeeping gene values (Hprt, and Tbp for Fig. 4, ubiqui-
tin C, beta-actin and Hprt for Supplementary Fig. 2). The followingprimers were used: Il7A_fwd CTC AGA CTA CCT CAA CCG TTC C and
Il7A_rev GTG CCT CCC AGA TCA CAG AAG; IFNγ_fwd AAA GAC AAC
CAG GCC ATC AGC and IFNγ_rev TGG CGA TGC TCA TGA ATG C;
Gata3_fwd CAC GAT CCA GCA CAG AAG GC and Gata3_rev GGT CTC
CGT TAG CGT TCC TC; Il10_fwd GAC GCT GTC ATC GAT TTC TCC and
Il10_rev CAG TAG ATG CCG GGT GGT TC; Hprt_fwd CTC ATG GAC TGA
TTA TGG ACA and Hprt_rev GCA GGT CAG CAA AGA ACT TAT; Tbp_fwd
GGG GAG CTG TGA TGT GAA GT and Tbp_rev CCA GGA AAT AAT TCT
GGC TCA; Ubc_fwd AAG GTC AAA CAG GAA GAT ACT CG and Ubc_rev
CTA AGA CAC CTC CCC ATG AAA C; Sox8_fwd AGA CCC TGG GCA AGC
TGT and Sox8_rev GGG TGG TCC TTC TTG TGC T; Cnp_fwd AAA TTC
TGT GAC TAC GGG AAG G and Cnp_rev GCC GTA AGA TCT CCT CAC
CA; Mbp_fwd GCT TCT TTA GCG GTG ACA GG and Mbp_rev CCT TGT
ACA TGT GGC ACA GC; Plp_fwd GCT AGG ACA TCC CGA CAA G and
Plp_rev CAA ACA CCA GGA GCC ATA CA; Mag_fwd AAC CAG TAT GGC
CAG AGA GC and Mag_rev GTT CCG GGT TGG ATT TTA CC; Mog_fwd
GCC GTG GAG TTG AAA GTA GAA G and Mog_rev AGT TTT CCT CTC
AGT CTG TGC. Additional primer sequences are available upon request.
Histopathological analyses
Animals were perfused via the left heart ventricle with PBS followed
by 4% paraformaldehyde. Paraformaldehyde-ﬁxed 3–5 mm thick
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in xylol, rehydrated and then stained with H&E and Luxol Fast Blue
(Klüver, KL) to assess tissue inﬂammation and demyelination, respec-
tively. The inﬂammatory index (I.I.) and demyelination score (DM)
were determined from the number and size of demyelinating lesions
in each animal on at least ten complete spinal cord cross-sections as
previously described (Storch et al., 1998).
Statistical analyses
p-Values for daily mean clinical EAE scores between the groups were
calculated with Wilcoxon matched pairs rank test in the Rcmdr package
of R software (R version 2.9.2 and Rcmdr version 1.5-4). p-Values for dif-
ferences in linear regression clinical EAE slopes were calculated with
ANCOVA in GraphPad Prism software (San Diego, CA). Demyelination
scores, cell numbers and percentages and expression levels between the
groupswere testedusing1-wayANOVAwithKruskal–Wallis test formul-
tiple comparisons, two-tailed unpaired t-test and Mann–Whitney test
and differences in frequency of occurrence of demyelinating lesions
were tested using Fisher's exact test in GraphPad Prism software.
Results
Treatment with VPA, T3 and VPA/T3 affects encephalitogenic CD4+ T cells
in vitro
HDAC inhibition has been shown to modulate encephalitogenic
CD4+ T cells (Ge et al., 2013; Lv et al., 2012; Zhang et al., 2012), while
little is known about the effects of thyroid hormone on these cells. There-
fore, we treatedMBP63–88-speciﬁc T cell lines, which express HDACs and
T3 receptor alpha and beta (data not shown), with VPA and T3 for ﬁve
days in vitro. VPA and VPA/T3 strongly reduced T cell proliferation and
frequency of total IL-17-producing cells, Th17 cells and IFN-γ/IL-17 dou-
ble positive cells (Figs. 1A, B), while VPA/T3 leads to an increase in
IFNg+IL-17− cells (Supplementary Fig. 1). T3 alone had no effect on T
cell proliferation but showed small but signiﬁcant effect on frequency
of IL-17-producing cells (Figs. 1A, B). Western blot analysis demonstrat-
ed increased levels of lysine 9 acetylation of histone H3 in VPA and VPA/
T3 treated T cells, but not in T3 treated cells (Fig. 1C). Nevertheless, T3
potentiates the effects of HDAC inhibition on H3 acetylation (Fig. 1C).0
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Fig. 3. Treatment with VPA/T4 ameliorates clinical signs of EAE.Mean clinical EAE scores and a
with VPA/T4 (n= 8) and vehicle (n= 6), (B) female rats treated with VPA/T4 (n= 11) and v
(D) female rats treated with VPA/T4 (n= 15) and vehicle (n= 15). Animals were immunize
that received 200mg/kg VPA i.p. three times daily and 0.2 mg/animal L-thyroxin s.c. once daily
was initiated at the onset (A, C) or three–four days after the onset of EAE (B, D) (arrows indicat
affected animals are included. Error bars represent SEM. Differences betweenVPA/T4 and vehic
mean daily clinical scores and the slope, respectively (p b 0.05= *, p b 0.001= ***). (E) ScheTreatment of encephalitogenic CD4+T cells with VPA, T3, and VPA/T3 prior
to transfer into naïve rats reduces clinical signs of EAE
Treatment of MBP63–88-speciﬁc T cells with VPA/T3 could lead to
transient effects on the T cells,whichwould not be reﬂected upon trans-
fer in vivo. This scenario would be mirrored by consequent recovery of
the pathogenic function of the T cells upon transfer, when the cells are
no longer exposed to VPA/T3. In order to assess whether the effects of
HDAC inhibition and T3 on encephalitogenic CD4+ T cells are long last-
ing and persist in the absence of the original stimuli in vivo, T cell lines
treated with T3, VPA and combined VPA/T3 were injected into naïve DA
recipients. Strikingly, T cells treated with all combinations induced
milder EAE (Fig. 2) compared to vehicle treated cells, despite the fact
that the same number of cells was injected (10 million). While the
long-term efﬁciency of VPA and VPA/T3 in reducing clinical signs of
EAE is likely to be related to their effects on T cell proliferation and
frequency of Th17 and IFN-γ/IL-17 double positive cells, T3 is most
likely acting through alternative mechanisms. In order to investigate
these possibilities, we examined the individual and combinatorial ef-
fects of VPA/T3 on the expression of anti- and pro-inﬂammatory fac-
tors in MBP-speciﬁc T-cells (Supplementary Fig. 2). Consistent with
our ﬂow cytometry results (Fig. 1), we found that treatment of path-
ogenic T cells for 6 h with VPA, but not T3, leads to a dramatic down-
regulation of IL-17 expression. In contrast, we observed that VPA/T3
treatment leads to an increase expression of the anti-inﬂammatory
cytokines IL-10 and IL-13 at 48 and 96 h. We also observe a synergis-
tic effect at 96 h of VPA/T3 in increasing the expression of the regulatory
T-cell transcription factor Foxp3. IFNγ was not affected by VPA treat-
ment at 6 h, although it is up-regulated by HDAC inhibition at later
time points (Supplementary Fig. 2), consistentwith the effects observed
by FACS (Supplementary Fig. 1). In contrast, Cxcr3, the typical chemo-
kine receptor expressed by Th1 cells, is down-regulated by VPA. We
also observed a robust increase of the chemokine receptor Cxcr4 at all
time points upon VPA treatment. CXCR 3 and CXCR4 are also involved
in T-cell migration, which might be an additional mechanism by
which HDACis modulate the immune response. In sum, these results
suggest that inhibition of IL-17 and possibly other players that are
part of the Th17 phenotype might be more relevant for EAE initiation
than the increase in IFNg/Th1 in the periphery.
Most of the genes affected by VPA were not affected by T3 (Supple-
mentary Fig. 2), suggesting alternative mechanisms of action. T3 leads0
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Fig. 4. Higher expression of Sox8 and myelin genes in cells isolated from the brain of animals treated with VPA/T4. Flow cytometry analysis of percentages of late pre-myelinating OPCs
(O4+Ki67+) out of the collected O4 population (A) and of total cells (B) in the spinal cord and the brain of VPA/T4 (n = 6–8) and vehicle (n = 5–7) treated animals 12 h after the
last treatment (15 days p.i.). At this point there were still no statistically signiﬁcant differences in clinical EAE between vehicle and treated animals. Representative gating of
O4+Ki67+ cells in the brain is given in (A). Gates: A: oligodendrocyte precursors (OPCs) (CD45+CD11b−) (Nakahara et al., 2005), oligodendrocytes (CD45+CD11b−), and lympho-
cytes (CD45++CD11b−); B: monocytes/macrophages (CD45++CD11b++); C: microglia (CD45+CD11b++); D: late OPCs and oligodendrocytes (O4+); E: late OPCs
(O4+Ki67+). Cells were isolated from the CNS, stained and acquired by ﬁxed time as described in Materials and methods. (C) Quantitative qPCR analysis of the oligodendrocyte
transcription factor Sox8 andmyelin genes (CNPase,Mbp, Plp,Mag andMog) in cells isolated fromthe spinal cord and the brain of VPA/T4 (n=8) and vehicle (n=8) treated animals 12h after
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226 G. Castelo-Branco et al. / Neurobiology of Disease 71 (2014) 220–233to a slight increased expression of Ccr7 at 6 h and a similar trend is ob-
served for CD62L at 6 h and 96 h. These results could suggest a role of T3
in preventing lymphocytes to emigrate from the lymph nodes and
migrate to the CNS. Further investigation will be required to identify
the pathways by which T3 reduces the pathogenicity of MBP-speciﬁc
T cells in vivo.
Acute treatment with VPA and T4 ameliorates clinical signs of established
myelin oligodendrocyte glycoprotein (MOG)-EAE in DA rats
Current therapeutic approaches for rodent EAE based onHDACis rely
on preventive and chronic daily treatment (Ge et al., 2013; Lv et al.,
2012; Zhang et al., 2012). Given the observed long-term effects ofthyroid hormone and VPA in encephalitogenic CD4+ T cells (Figs. 1,
2) and our previous observations that HDAC inhibition promotes oligo-
dendrocyte differentiation from neural stem cells and OPCs only in the
presence of T3 (Castelo-Branco et al., 2014), we investigated the thera-
peutic potential of combining the immunomodulatory effects of VPA
and the remyelinating effects of T3 precursor L-thyroxine (T4) in acute
treatment of MOG-induced EAE in DA rats. We targeted speciﬁcally
the onset of clinical signs of EAE, a window where inﬂammation and
recruitment of OPCs for remyelination are peaking (Fig. 3E). Three alter-
nate treatment days with VPA and T4, spread over a period of ﬁve days,
signiﬁcantly ameliorated the clinical signs of MOG-EAE (Figs. 3A–D).
Treatment at the peak of the ﬁrst bout (Figs. 3B, D) was as efﬁcient as
treatment right after the onset of disease (Figs. 3A, C) further conﬁrming
227G. Castelo-Branco et al. / Neurobiology of Disease 71 (2014) 220–233the therapeutic potential of combined VPA/T4. Moreover, this short
treatment induced a prolonged and persistent reduction of severity of
EAE, evenwhen a secondﬂare of the disease occurs (Figs. 3B, C). This ef-
fect was independent of the initial disease severity as the treatment
showed desired results in mild (Figs. 3A, D) as well as severe forms of
EAE (Figs. 3B, C), or of gender (Fig. 3A, male rats treated with VPA/T4
(n = 8) and vehicle (n = 6); Figs. 3B, C and D, female rats treated
with VPA/T4 (n = 11, 15 and 15, respectively) and vehicle (n = 10,
15 and 15)).Higher expression of myelin genes in the brain, but not spinal cord, upon
treatment of EAE with VPA and T4
To investigate if the clinical effect of VPA and T4 is accompanied by
an effect onNSC/OPCdifferentiation or lineage progression,mononucle-
ar cells were isolated from the spinal cord and the brain 12 h after the
last treatment (5 days after the initial treatment). The isolation protocol
with Percoll involves the removal of myelin and thus of many of the as-
sociated oligodendrocytes, while preserving immune cells, OPCs and
pre-myelinating cells (expressing Mbp, CNPase and Plp, see Material
and methods) (Colello and Sato-Bigbee, 2001). We observed by ﬂow
cytometry a trend for an increase in the % of late pre-myelinating
OPCs (O4+Ki67+) out of the collected O4 population in the brain,
but not in the spinal cord (Fig. 4A, gate D). There was a similar trend
for an increase in the % of late pre-myelinating OPCs out of total cells
(Fig. 4B). Concomitantly, we observed by qPCR higher expression of
Sox8, a transcription factor involved in terminal oligodendrocyte differ-
entiation (Stolt et al., 2004) and a direct HDAC target (Castelo-Branco
et al., 2014) in the brains of treated animals (Fig. 4C) compared to un-
treated animals. Likewise, all major myelin genes, CNPase, Mbp, Plp,
Mag andMog, displayed signiﬁcantly higher expression in the brain of
treated animals (Fig. 4C). These results suggest that one of the mecha-
nisms by which treatment with VPA and the T3 precursor might be act-
ing in the brain is by promoting oligodendrocyte lineage progression.CD4+ Foxp3-
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Fig. 5. Treatmentwith VPA/T4 limits entry of Th1 cells in the brain. Flow cytometry analysis of nu
double positive (CD4+Foxp3−IFN-γ+IL-17+) and Th17 (CD4+Foxp3−IFN-γ−IL-17+) cell
ed animals 12 h after the last treatment (15 days p.i.). Representative gating of T helper cells in th
as described inMaterials and methods. Each circle represents cells from a different animal. Erro
lated with Mann–Whitney test (p b 0.05 = *, p b 0.01 = **).Treatment of EAE with VPA and T4 modulates the immune response and
reduces numbers of Th1 cells in the brain
We next investigated if the effect on clinical disease and gene
expression in the brain can be attributed to changes in the immune
response. To that end, we measured the amount of CNS-inﬁltrating
Th1 and Th17 cells 12 h after the last treatment (5 days after the initial
treatment). We observed a tendency for lower absolute numbers and
percentages of Th1 cells (CD4+Foxp3− IFN-γ+IL-17−) in the spinal
cord of treated animals, while numbers and percentages of total
CD4+ T cells and Th17 cells (CD4+Foxp3− IFN-γ− IL-17+) did not
differ between the groups (Fig. 5A). However, the effect of VPA in com-
bination with T4 on CD4+ T cell inﬁltration became prominent in the
brain. We observed a signiﬁcantly lower number of total CD4+ T cells
in the brain of treated animals (Fig. 5B), with a signiﬁcantly less fraction
of Th1 cells inﬁltrating the brain in treated animals. There was also a
tendency for less inﬁltrating Th17 cells (Fig. 5B), in accordance with
our in vitro data (Fig. 1). While no difference in proliferation was seen
in IFNg+IL-17+ or IFNg− IL-17+ populations (data not shown),
IFNg+IL-17− T cells presented a proliferative impairment in the CNS,
as evidenced by staining for Ki67 (Supplementary Fig. 3).
Treatment of EAEwith VPA and T4modulates immune response in peripheral
tissues
Peripheral lymphoid organs in which the priming of T cells occurs
represent a very different environment compared to the target CNS
organ. Myelin-speciﬁc Th17 cells arising in the periphery are the most
potent in entering the CNS but once in their target tissue they convert
to IFNγ producing cells (Codarri et al., 2011; Hirota et al., 2011). The
effect of VPA together with T4 on CD4+ T cells was also observed in
the peripheral immune tissues. The treatment led to signiﬁcantly
lower proliferation of CD4+ non-regulatory T cells in the spleen
(Fig. 6A) and lymph node (Supplementary Fig. 4) and to higher prolifer-
ation of regulatory CD4+ cells in the spleen (Fig. 6). This latter result is0
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ment of MBP63–88-speciﬁc T cells with VPA/T3 (Supplementary Fig. 2).
When stimulated with an unspeciﬁc stimulus (Concanavalin A),
CD4+ T cells from the lymph nodes of treated animals displayed less
propensity to produce IL-17, reﬂected in lower percentage of Th17
and IFN-γ/IL-17 double positive cells (Fig. 6B), in accordance with our
in vitro data (Fig. 1). Taken together, the data indicate that the com-
bined treatment with VPA and T4 affects immune reactions both at
the periphery and in the CNS.
Treatment of EAEwith VPA and T4 prevents inﬂammatory demyelination in
the brain
Finally, we investigated if the early treatment-induced changes in
the immune response and OPC differentiation led to changes in*
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Fig. 6. Treatmentwith VPA/T4 decreases proliferation of effector CD4+T cells in the peripheral
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between VPA/T4 and vehicle treated groups were calculated with Mann–Whitney test (p b 0.0histopathology of the CNS that explain the persistent clinical effect.
We performed histopathological analyses to assess inﬂammation and
subsequent myelin loss in the CNS 20 days after the last treatment
(Figs. 7, 8; Table 1). Both treated and untreated groups had inﬂammato-
ry demyelinating lesions in the spinal cord (Figs. 7A, 8A Table 1). Never-
theless, myelin was generally better preserved in the treated animals,
while the highest impact of the treatmentwas observed in the brain ac-
companied with a tendency towards lower demyelination in the spinal
cord. Notably, only one of 10 treated animals developed inﬂammatory
lesions in the brain compared to untreated animals (5/8) in which de-
myelination spread to optic nerves and even other parts of the brain
(Figs. 7B, 8B; Table 1). Thus, early combined treatment with VPA and
T4 led to prolonged reduced demyelination in the CNS and prevented
dissemination of the pathogenic inﬂammatory demyelination to the
brain.*
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Our ﬁndings demonstrate a therapeutic impact of combining VPA
with thyroid hormone to treat MS-like disease in rats. A three-
alternate day acute treatment initiated in already established disease
induced signiﬁcant persistent amelioration of clinical signs and brain
pathology. The effectiveness of the treatment could be attributed to its
strong immunomodulatory properties in combination with the effect
on oligodendrocyte lineage progression.
HDAC inhibitors have been shown to have good prophylactic effects
in rodent EAE (Camelo et al., 2005; Ge et al., 2013; Lv et al., 2012; Zhang
et al., 2012, 2010). However, the therapeutic potential in already
established disease is much clearer in our experiments with combined
T4 treatment. In previous studies, the treatment initiated at the onset
of EAE had a modest effect in MBP68–84-induced EAE in Lewis rats
(Zhang et al., 2012) and treating MOG35–55-induced EAE in C57BL/6
mice after onset had a substantial effect; however, the treatment was
administered daily for the remainder of disease (Lv et al., 2012). Our
data show that we can achieve a signiﬁcant persistent amelioration of
EAE in rats with a short course of combined treatment. Cycles of shorter
treatments would be more desirable in clinical settings due to the
known adverse effects of HDACis including diarrhea, vomiting, fatigue,
thrombocytopenia and cardiac problems.
We studied the effect of treatment in MOG-induced EAE in DA rats.
MOG is aminor surface-exposedmyelin antigen known to be encephali-
togenic inmost studied species (von Budingen et al., 2001). In contrast to
other EAE models induced by a single CNS antigen, the pathophysiology
of MOG-EAE is more complex and mimics many features of its human
counterpart. Themajority of animals develop a chronic relapsing disease
course that also occurs in ~85% of MS patients. In the DA strain, females
are more affected thanmales (Storch et al., 1998), and similarly a higher
incidence of MS is observed in women. Pathology is typically character-
ized by perivascular inﬂammation, dominated by T cells andmacrophages, and large focal demyelinated plaques (Storch et al.,
1998). The lesions are inducedby the combined effect of encephalitogen-
ic T cells and demyelinating anti-MOG antibodies (Iglesias et al., 2001).
Most frequently, the lesions occur in the spinal cord, the optic system,
the cerebellum and the brain stem, which are also sites of predilection
in MS (Vinken and Bruyn, 1970).
In EAE, encephalitogenic responses are initiated in peripheral lym-
phoid organs from where T cells migrate to the CNS where they are
reactivated, recruit other cells and start a cascade of immune reactions.
In the peripheral lymphoid tissues, we observed themost striking inﬂu-
ence on reduced proliferation of conventional effector CD4+ T cells by
our combined treatment. This is in line with previously demonstrated
anti-proliferative and apoptotic effects of HDACis (Dagtas et al., 2009;
Lv et al., 2012; Moreira et al., 2003; Zhang et al., 2012) and our data
with encephalitogenic T cell lines in vitro. Simultaneously, we observed
an increase in proliferation of Foxp3+ Tregs, which are protective in
EAE, previously shown to be induced by inhibition of HDACs (Lucas
et al., 2009; Tao et al., 2007). Thus, the treatment restricted expansion
of activated and encephalitogenic T cells in the periphery. The effect
was more prominent on IL-17-producing cells, resulting in fewer Th17
and IFN-γ/IL-17 double positive cells ex-vivo after stimulation. Direct
VPA/T3 treatment of MBP63–88-speciﬁc T cell lines used to induce pas-
sive EAE also reduced the frequency of Th17 cells. The pathogenic role
of IL-17-producing Th17 cells in EAE is well established (Langrish
et al., 2005; Park et al., 2005). Th17 cells are able to enter the CNS with-
out a compromised blood brain barrier and to initiate an inﬂammatory
cascade and a secondwave of inﬁltration by Th1 and Th17 cells (Reboldi
et al., 2009). Both Th1 and Th17 cells have shown pathogenic roles in
EAE (Baron et al., 1993; Kroenke et al., 2008; Segal and Shevach, 1996;
Stromnes et al., 2008). Additionally, myelin-speciﬁc Th17 cells arising
in the periphery are the most potent in entering the CNS but once in
their target tissue they can convert to IFN-γ producing Th1 cells
(Codarri et al., 2011; Hirota et al., 2011). Indeed, we found signiﬁcantly
A1 A2
A3 A4
B1 B2
B3 B4
Fig. 8.Reduced brain tissue inﬂammation/demyelination in animals treatedwith VPA/T4. Group representative images of the parafﬁn embedded (A1–4) spinal cord and (B1–4) brainwith
optic nerve tissue cross-sections of rats subjected to VPA/T4 and vehicle treatment harvested on day 38p.i. Histopathological analyseswere performed on at least 10 cross-sections stained
withH&E (A1, 3; B1, 3) andKlüver (A2, 4; B2, 4) to detect inﬂammation anddemyelination, respectively. Rats treatedwith VPA/T4 showed less profoundmyelin loss and inﬂammatory cell
numbers in the spinal cord lesions (A3, 4), accompanied with an intact brain and optic nerves (B3, 4), while vehicle-treated CNS displayed extensive inﬂammation/demyelination in the
spinal cord (A1, 2) aswell as a complete demyelination of both optic nerves (B1, 2). Selected rats exhibit the group-representative neuropathology, whereas the complete analysis, done in
an unbiased fashion on a minimum of ten cross-sections located on comparable spinal cord levels of each animal, is presented in Fig. 7.
230 G. Castelo-Branco et al. / Neurobiology of Disease 71 (2014) 220–233less CD4+ T and Th1 cells inﬁltrating the brain and a tendency for less
Th17 cells. As such, the differential effect of VPA/T3 in vitro and in
peripheral tissues versus the brain might be due to the conversion of
Th17 cells into Th1 cells in the CNS.
It has been shown that preventive treatment with VPA induces sig-
niﬁcant changes in the rodent spinal cord under EAE (Ge et al., 2013;
Lv et al., 2012; Zhang et al., 2012). Similar to these observations, the
combinatorial treatment in our study generally reduced inﬂammatory
demyelination in the CNS, with the highest impact observed in the
brain. Moreover, this was accompanied with signiﬁcantly higher
expression of myelin genes and reduced inﬂammatory demyelination
also in the brain. It is likely thatwe observe only tendencies in the spinal
cord as the pathology in the spinal cord, including prominentinﬂammation and demyelination, is already well established at the
time of the treatment and assessment. Comparing to the previous stud-
ies (Ge et al., 2013; Lv et al., 2012; Zhang et al., 2012), our considerably
shorter treatment had equally beneﬁcial long-term clinical effects.
While the EAE score is mainly based on locomotor activities, we do
observe ascending paralysis (which is part of our scoring system) as dis-
ease progresses/worsens, and often secondary brain-related effects
such as balance disturbance at later time points, pointing to a spread
of inﬂammation possibly from the spinal cord to brain. VPA/T3 treat-
ment might be hindering or controlling early inﬂammatory sites in the
brain, while already established strong inﬂammatory inﬁltrates might
be less affected in the spinal cord, which is supported by CD4+ cell
counts in the brain versus spinal cord (Fig. 5). To our knowledge,
Table 1
Treatment with VPA/T4 reduces inﬂammatory demyelination in the CNS.
Onset of EAEa Duration of EAEa Cumulative EAE scorea Demyelination in the spinal cordb Demyelination in the brainb Lesional brain topographyb
VPA/T4 11 28 79 +++ −
11 28 69 +++ ++++ nn. optici
11 28 42 + −
11 18 32 + −
10 17 24 ++ −
13 15 20 +/− −
10 11 18 ++ −
14 15 18 + −
12 9 12 +/− −
11 6 10 +/− −
Vehicle 12 27 75 ++++ ++++ nn. optici
11 28 73 +++ ++++ n. opticus, chiasma opt, n. Trigeminus
10 29 69 ++++ ++++ hemisphere, cerebellum
11 28 67 ++++ ++++ nn. optici
11 28 44 ++ + n. opticus
12 9 14 + −
14 6 8 +/− −
12 4 4 +/− −
a The following disease parameterswere assessed for each animal: onset of EAE (the ﬁrst daywith clinical diseasemanifestation), duration of EAE (the number of dayswithmanifested
disease) and cumulative EAE score (the sum of daily clinical scores). Only animals that developed clinical signs of EAE were included in histopathological analysis.
b Demyelination score, assessed according to Storch et al., 1998 , and topography of demyelinating lesionswas established in VPA/T4 and vehicle treated animals 38 days p.i. (statistical
analysis presented in Fig. 7).
231G. Castelo-Branco et al. / Neurobiology of Disease 71 (2014) 220–233there is no further behavioral test to reﬂect EAE pathology in the rat
brain. It is possible that we would observe more dramatic effects on
the treatment if such test would be available.
Treatment of actively induced chronic EAE in DA rats with T4 does
not lead to a reduction of clinical signs, despite signiﬁcant effects on
remyelination (Fernandez et al., 2004). Treatment of encephalitogenic
T cells with T3 alone induces a modest reduction in frequency of IL-
17-producing cells (Fig. 1), leading to milder disease upon transfer
(Fig. 2).We observed a dramatic increase in lysine acetylation of histone
H3 in VPA and VPA/T3 treated T cells, but not by T3 alone. Nevertheless,
the effect of VPA on lysine acetylation of histone H3 was further ampli-
ﬁed by T3. More extensive studies will be required to investigate alter-
native roles of thyroid hormone in EAE, given multiple potential effects
of thyroid hormones on immune system (De Vito et al., 2011).
It has been recently shown that IL-17 can also target the OPCs in the
context of EAE, preventing their maturation and expression of myelin
genes (Kang et al., 2013). This ﬁnding highlights the necessity to target
not only inﬂammation but also myelin regeneration in the context of
MS. In the brain, we observed a trend for an increase of proliferating
late OPCs that start presenting oligodendrocyte differentiation markers
(such as O4) upon combined VPA and T4 treatment. Furthermore, we
observed a higher expression of the OPC-associated transcription factor
Sox8, a direct HDAC2 target, and of several myelin related genes. As
such, our results suggest that, as we observed in embryonic neural
stem cells andOPCs (Castelo-Branco et al., 2014), theHDACi and thyroid
hormone can overturn a repressive transcriptional checkpoint present
in NSCs/OPCs in the EAE brain that prevents their differentiation and
myelination. This is also in line with previous reports where knock-
down of the histone acetylase CBP/CREBBp leads to a reduction in
generation of OLs (Wang et al., 2010) and knock-out of the histone
deacetylase Sirt1 leads to increased remyelination upon lysolecithin in-
duced demyelination and delayed onset of paralysis in a chronic EAE
mouse model (Rafalski et al., 2013). However, the effects of histone
deacetylation on the differentiation of OPCs and myelination appear to
be context dependent, as conditional double knock-out of HDAC1 and
HDAC2 compromises the oligodendrocyte lineage through beta-
catenin stabilization (Ye et al., 2009) and HDAC inhibitors prevent
remyelination in the cuprizone model of demyelination (Shen et al.,
2008). Our results indicate that presence or absence of thyroid hormone
might be a key for the differential actions of HDAC inhibitors. Alterna-
tively, their differential activity could also reﬂect targeting of diverse
NSC/OPC populations. We noted an increase in myelin-related genesupon combined VPA and T4 treatment in the brain but not in the spinal
cord. This difference might be due to regional differences between NSC
and OPC populations in the brain and spinal cord. Further investigations
will be necessary to address the identity of the cells targeted by VPA/T4
in the CNS.
Our data indicate that a three-day combined treatment with VPA
and T4 after the onset of disease can produce persistent and clinically
relevant therapeutic effects in MOG-induced EAE in DA rats. This advo-
cates future efforts to develop novel treatments thatwould combine im-
munomodulatory and remyelinating properties of HDACis and thyroid
hormone to treat MS.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2014.08.019.
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